Quick Answer
CytomX Therapeutics, Inc. reported Research And Development Expense of $68.73 million for the year ending 2025.
- CytomX Therapeutics, Inc. showed a decrease of -17.6% in Research And Development Expense from 2024 to 2025.
- This data is from CytomX Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $3.92 million | Q1 2015: $4.66 million | Q2 2015: $5.03 million | Q3 2015: $9.16 million | Q1 2016: $13.37 million | Q2 2016: $12.71 million | Q3 2016: $13.34 million | Q1 2017: $14.58 million | Q2 2017: $28.08 million | Q3 2017: $28.92 million | Q1 2018: $22.46 million | Q2 2018: $25.55 million | Q3 2018: $27.55 million | Q1 2019: $36.38 million | Q2 2019: $30.84 million | Q3 2019: $27.97 million | Q1 2020: $42.81 million | Q2 2020: $24.07 million | Q3 2020: $24.05 million | Q1 2021: $22.37 million | Q2 2021: $26.10 million | Q3 2021: $29.14 million | Q1 2022: $30.56 million | Q2 2022: $31.16 million | Q3 2022: $30.37 million | Q1 2023: $21.18 million | Q2 2023: $20.67 million | Q3 2023: $16.45 million | Q1 2024: $22.05 million | Q2 2024: $25.17 million | Q3 2024: $21.37 million | Q1 2025: $18.87 million | Q2 2025: $13.32 million | Q3 2025: $15.30 million.
- Over the full 13 years of available data (2013 to 2025), CytomX Therapeutics, Inc.'s Research And Development Expense has grown by 531.1%.
- Historical annual values: Fiscal year 2025: $68.73 million | Fiscal year 2024: $83.38 million | Fiscal year 2023: $77.68 million | Fiscal year 2022: $111.65 million | Fiscal year 2021: $114.19 million | Fiscal year 2020: $112.94 million | Fiscal year 2019: $131.62 million | Fiscal year 2018: $103.87 million | Fiscal year 2017: $92.28 million | Fiscal year 2016: $54.76 million | Fiscal year 2015: $28.36 million | Fiscal year 2014: $28.30 million | Fiscal year 2013: $10.89 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: